



April 20, 2020
JCR Pharmaceuticals Co., Ltd.

Translation

Notice of Completion of Acquisition of ArmaGen, Inc.

JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced today that it has completed the previously announced acquisition of ArmaGen, Inc., a privately held US biopharmaceutical company headquartered in San Diego, California (“ArmaGen”). (See related news release dated March 26, 2020.)

As a result of this acquisition, ArmaGen has become a wholly-owned subsidiary of JCR, providing JCR with a full access to its portfolio of intellectual property rights applicable to a broad disease spectrum, including lysosomal storage disorders (LSDs) in several key markets that ArmaGen owns. Leveraging ArmaGen's IP portfolio and abundant knowledge, JCR aims to harness the consolidated strengths of both companies to further accelerate global development of unique treatment options for LSD patients as expeditiously as possible.

This acquisition is expected to have a minor impact on JCR's consolidated financial results for the year ending on March 31, 2021.

[About JCR Pharmaceuticals]

JCR is a specialty pharma company engaged in the research, development, manufacturing and marketing of biopharmaceuticals and regenerative medicine with a focus on rare diseases. Its philosophy, “Contributing towards people’s healthcare through pharmaceutical products” drives JCR to create innovative pharmaceutical products as value-added treatment options for the under-served patient populations

[Cautionary Statement Regarding Forward-Looking Statements]

This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as “believe,” “estimate,” “anticipate,” “intend,” “plan,” “will,” “would,” “target” and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors’ pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions.

This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

ir-info@jcrpharm.co.jp

END

###